A61K 38/2086
Il-13 to il-16
Official title: {IL-13 to IL-16}
A61K38/2086 (Il-13 to il-16) appears on 368 US grants and 799 published applications in this corpus.
Search patents in A61K- Granted patents
- 368
- Published applications
- 799
- Assignees
- 361
- Inventors
- 1,332
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 2 |
| 2002 | 3 | 11 |
| 2003 | 1 | 6 |
| 2004 | 1 | 16 |
| 2005 | 1 | 3 |
| 2006 | 2 | 12 |
| 2007 | 1 | 23 |
| 2008 | 4 | 6 |
| 2009 | 1 | 14 |
| 2010 | 2 | 18 |
| 2011 | 4 | 16 |
| 2012 | 8 | 16 |
| 2013 | 11 | 17 |
| 2014 | 9 | 25 |
| 2015 | 20 | 33 |
| 2016 | 22 | 36 |
| 2017 | 24 | 31 |
| 2018 | 26 | 34 |
| 2019 | 30 | 64 |
| 2020 | 25 | 56 |
| 2021 | 34 | 65 |
| 2022 | 35 | 69 |
| 2023 | 25 | 64 |
| 2024 | 24 | 57 |
| 2025 | 36 | 61 |
| 2026 | 17 | 44 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment of immunosuppressed subjects15 Sep 2026US 12,734,216 B2NantCell, Inc.
- Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer18 Aug 2026US 12,708,653 B2Endeavor Health Clinical Operations
- Compositions and methods regarding engineered and non-engineered γδ T-cells for treatment of solid tumors4 Aug 2026US 12,698,340 B2Adicet Therapeutics, Inc.
- Compositions and methods regarding engineered and non-engineered γ δ T-cells for treatment of hematological tumors28 Jul 2026US 12,692,319 B2Adicet Therapeutics, Inc.
- IL-2/IL-15R beta gamma agonist dosing regimens for treating cancer or infectious diseases23 Jun 2026US 12,661,387 B2Cytune Pharma
- Targeted lipid nanoparticles for treating central nervous system injuries8 Oct 2026US 2026/0306665 A1Wisconsin Alumni Research Foundation
- Engineered immune cells for treating cancer in combination with il-2/il-15 receptor beta-gamma agonists24 Sep 2026US 2026/0284145 A1Sotio Biotech Inc.
- Il-15-based molecules and methods of use thereof3 Sep 2026US 2026/0256886 A1Altor BioScience Corporation
- Method and composition for preventing or treating myopia20 Aug 2026US 2026/0240925 A1Tsubota Laboratory, Inc.
- Anti-btn3a antibodies and their use in treating cancer or infectious disorders20 Aug 2026US 2026/0242480 A1Centre National de la Recherche Scientifique (CNRS)
Most cited
By later US patents
- Handheld electromechanical surgical system627US 10,932,784 B2Covidien LP · 2021
- Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy258US 8,034,334 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2011
- Adoptive cell therapy with young T cells191US 8,383,099 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2013
- Adoptive cell therapy with young T cells137US 9,074,185 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2015
- Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra128US 8,124,084 B2University of Connecticut · 2012